Mark Cuban’s latest move to disrupt the pharmaceutical supply chain is expanding — this time, tackling the injectable drug market through a new partnership with distributor Morris & Dickson.
His company, Mark Cuban Cost Plus Drug Co., is partnering with Morris & Dickson, a full-line and specialty pharmaceutical distributor, to improve access to injectables nationwide.
The collaboration, announced April 14, aims to mitigate drug shortages, streamline procurement and provide equitable access to providers of all sizes. It also promotes sourcing flexibility by removing volume commitments, according to a news release.
“This partnership reshapes the supply chain for injectable medications,” Mr. Cuban said in a statement. “Together, we’re not just filling gaps, we’re creating a more transparent, efficient, and patient-centered system.”
Morris & Dickson, which offers next-day deliveries to health systems, pharmacies and alternative care facilities, will initially focus on distributing injectable medications through the partnership. The companies plan to expand into other drug categories in the future.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
